Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. - Wikidata - awgldk - TriplyDB

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

http://www.wikidata.org/entity/Q34631210

about

Treatment of colorectal cancer in the elderly Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients.Current status of gene expression profiling to assist decision making in stage II colon cancer Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases.Colorectal cancer surgery remains effective with rising patient age.A comparative study of two PODXL antibodies in 840 colorectal cancer patients.Immune cells: plastic players along colorectal cancer progression The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study.The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients.The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort.Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors.Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies Podocalyxin is a marker of poor prognosis in colorectal cancer Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?Differential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy.Cost profiles of colorectal cancer patients in Italy based on individual patterns of care.Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis.Prognostic value of HLA class I expression in patients with colorectal cancer.Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy.Nomograms to predict survival after colorectal cancer resection without preoperative therapy.Gene Signatures in Stage II Colon Cancer: A Clinical Review.MiR-320e is a novel prognostic biomarker in colorectal cancer.The prognostic importance of miR-21 in stage II colon cancer: a population-based study.Chemotherapy for Stage II Colon Cancer.Methods in comparative effectiveness research.Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy?Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer.Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy.A new simple morphology-based risk score is prognostic in stage I/II colon cancers Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer

P2860

Q26781457-08B8CC2F-6C42-4860-895F-6AF8EF751B72 Q27496689-9AA7B911-1066-4242-A860-F29D4E3CE31C Q27852108-2EAC8E15-BBD4-4888-B580-6A311DDB1297 Q27853326-41B84CED-56AC-4DD7-8D19-D978A34861DD Q28252178-9F358D48-A182-487E-AF73-6B63F1EB2688 Q30780611-06C7E501-D6D4-46A1-9D61-B94BCA06B335 Q31056926-BE137AB7-F14C-4360-9130-B3B0127AE125 Q33637755-9042592C-C953-43EA-B0BB-260426E60862 Q33829763-D3A21E28-49B8-4C81-B192-6B5AB84BD852 Q33854762-F31DC76F-A66E-473B-9365-1E736C7B0021 Q33912187-F60BBABE-D147-4D1B-AEB4-1D685BF5DD14 Q33938468-87BC5EF4-7D28-4833-B21E-3E08385DF306 Q33985586-65C4AD84-4366-4199-8B36-1A4E20FA9064 Q34071833-1CF53671-D73A-4047-838B-F42853C2044D Q34216044-17FAC7CD-34B0-422A-8E3A-B53F592A3FEE Q34239837-8AD8CF7F-A47A-46FD-B4F4-84DBFAE67F50 Q34283673-DA2131E6-53A6-4311-AD9F-9A3808843431 Q34343946-E97F55EB-28FC-4AE9-B3F0-0EDDC3F0E19E Q34368278-5D5EFCE2-CECA-47D5-8C2E-F0AF28ECC1EA Q34485223-8664ED42-6B70-4A4F-9E72-A7AF223871F7 Q34533164-53B8D625-AE34-4FC2-85FC-A6EBA2D2E0AC Q34630015-F67E00E8-8EE5-4B04-94F1-27E8CCCE6E9F Q34683946-D675DE4B-0F72-4A82-A65F-7AA463C90DDA Q34798586-0CCE9130-CA1F-499E-BE62-34B1D041B37A Q35057318-D6C4FCC0-A668-4684-B2F5-BD251334F004 Q35067307-23315710-3CAB-4E9A-8322-2C8B5A6A1BC6 Q35108620-68262E52-8529-4D53-BB0D-24A63E9F086D Q35475513-413DF9F8-87EC-49A4-9DCE-1B4BB4277A81 Q36076656-5A6118EF-A434-4E33-B2F0-B7D27DC12DD6 Q36110653-A1A4156F-7ADF-4896-8736-3FB6C58A8582 Q36247103-2230AABE-6E28-4354-84D5-B2C91981784D Q36286673-FE0903DE-ED1D-4CA8-9B9B-0E5D95C85B80 Q36287985-027E74D3-E07E-46C1-86DD-189822C94F8A Q36304759-65DD0095-826E-4A98-AB62-E2A7E024F059 Q36417734-C6A9F6FB-8242-4AF1-B8BB-0D5F98518A77 Q36444990-9522AE1E-D998-4FB8-AAF9-3E84BCA93217 Q36594047-11A772F5-7C19-4253-8AB1-B0F0D3C65B40 Q36729590-68F72AAD-9839-43F1-8F8F-78A1BCA4ADCF Q36902960-DD781B38-42EF-43AD-8799-630164E194CB Q37100057-9B6C37F9-028E-4C3F-A4EB-2AA5D0B637AB

P2860

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

http://www.wikidata.org/entity/Q34631210

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@ast

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@en

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@nl

type

label

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@ast

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@en

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@nl

prefLabel

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@ast

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@en

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@nl

P1433

Q34631210-4FDA80BC-FCD3-4306-A5AA-21414EB16218

P1476

Q34631210-8329D525-6CEB-48EE-90DF-E6C4A86A032E

P2093

Q34631210-11AD1489-F4DF-44C0-9C82-E44BEC7A6144

Q34631210-160290FD-8284-47AE-A9F1-656F21C9DF69

Q34631210-48BD64B4-EC42-4450-B884-FC8475515BDB

Q34631210-82018FCE-F17E-4CBC-8324-34A6C0813F42

Q34631210-C7B79100-F453-40AD-8861-B9FC574657F3

Q34631210-FBB15A4D-3692-4BD9-B465-FA2DFA64786F

P2860

Q34631210-063DCCFE-8D22-4439-9388-C0926D97A1C9

Q34631210-077257DA-0F97-4E7D-A3B8-C4FCFFB28E5C

Q34631210-09EE6DB2-38F6-429D-ADA6-FC25CF0BF21F

Q34631210-127DFE8E-34EA-404F-9B86-5428A852116B

Q34631210-177A3A02-BC2F-4808-9565-54707D57C341

Q34631210-3B6D8B92-9569-40BB-91B7-0AFA73365E72

Q34631210-58AB6C6D-49DE-4105-9F54-3647F8D01389

Q34631210-58D6761C-D67F-419F-AEC2-A4C2E799902C

Q34631210-5F547F54-033C-4D81-AFAD-C38383273BD4

Q34631210-773AD99E-5897-47F2-955A-53D3072ADA30

P304

Q34631210-F4C1297E-E1AE-4865-85EA-D961ED6D5B20

P31

Q34631210-094E1207-06A8-4854-BB03-68788AFEFA57

P356

Q34631210-5C98C49E-A614-4E34-AD90-279C59FC54EF

P407

Q34631210-2739C1A1-D669-466E-96A7-47CE9F80F94A

P433

Q34631210-CB7EFE96-C4D1-45B1-AC0E-661507FBFEC5

P478

Q34631210-FE37ACB7-C11D-4CB2-95B7-8430429BAB2D

P50

Q34631210-D1B6AA8B-4DC3-4FC1-82D3-6D90630EDD98

P577

Q34631210-EFCF2454-793A-462D-9F51-700E7E4AD8C2

P5875

Q34631210-9C7285D7-6349-4294-ABCB-889D74055E74

P698

Q34631210-1625B048-A252-4338-8D0E-C5DC8D54FD1A

P921

Q34631210-0CCA31EE-A423-4EAB-8969-B71E331267F1

P932

Q34631210-CA7EA18E-F981-445E-BC89-A4309CD814E3

P356

JCO.2010.34.3426

P1433

Journal of Clinical Oncology

P1476

Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

@en

P2093

Charles P Heise

http://www.w3.org/2001/XMLSchema#string

David Yu Greenblatt

http://www.w3.org/2001/XMLSchema#string

Erin S O'Connor

http://www.w3.org/2001/XMLSchema#string

Jinn-Ing Liou

http://www.w3.org/2001/XMLSchema#string

Maureen A Smith

http://www.w3.org/2001/XMLSchema#string

Noelle K LoConte

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.

Readmission after colectomy for cancer predicts one-year mortality

Should Dukes' B patients receive adjuvant therapy? A statistical perspective.

Using diagnoses to describe populations and predict costs.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

P304

3381-3388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.34.3426

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Ronald E Gangnon

P577

2011-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51520619

http://www.w3.org/2001/XMLSchema#string

P698

21788561

http://www.w3.org/2001/XMLSchema#string

P921

P932

3164243

http://www.w3.org/2001/XMLSchema#string